Sharon Bio-Medicine (SHARON BIO-MEDICINE) Q4 FY23 Sees Revenue and Profit Plummet in a Challenging Final Quarter
The API and formulation maker ended FY23 with a sharp sequential and yearly drop in sales and earnings, highlighting operational pressures.
Sharon Bio-Medicine's Q4 FY23 saw revenue fall 23% from the previous quarter and profit drop 81%, capping a volatile year. The weak finish underscores margin pressures in a competitive API market.
Sharon Bio-Medicine closed its financial year with a quarter that reversed much of its recent momentum. The active pharmaceutical ingredient (API) and formulation maker saw both sales and profit contract sharply, pointing to underlying cost and demand pressures that intensified as the year ended.
The numbers show a steep decline. Revenue for the March quarter stood at ₹44.24 crore, down 11% from a year ago and a steep 23% drop from the December quarter. Profit fell even harder, dropping 61% year-on-year to ₹1.8 crore and collapsing 81% sequentially. The net profit margin shriveled to 4.1% from 16.4% just three months prior.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
| Metric | CurrentQ4 FY23 | PreviousQ3 FY23 | Same quarter LYQ4 FY22 |
|---|---|---|---|
| Revenue (₹ Cr) | 44.24YoY -11% | 57.74 | 49.77 |
| Profit (₹ Cr) | 1.80YoY -62% | 9.47 | 4.68 |
| Net Profit Margin (%) | 4.1YoY -56% | 16.4 | 9.4 |
A Year of Two Halves
The weak fourth quarter capped a year of stark contrasts. For the full FY23, the company's revenue grew 21.8% to ₹192.22 crore and profit jumped 76.9% to ₹19 crore. This annual strength, however, was built on a very strong middle two quarters, with Q1 showing a loss and Q4 a sharp deceleration. The annual profit figure also benefited from a significant one-time item. According to an SPTulsian.com analysis, the proforma net profit for the combined entity (including its acquirer) included a one-time writeback of ₹54 crore in liabilities from Sharon Bio-Medicine.
The Margin Squeeze
The drastic compression in profitability is the quarter's central story. The research suggests the company's standalone business has faced margin pressure, with its net margin contracting in recent years. For Sharon specifically, SPTulsian.com noted it clocked a net margin of just 5% for the full FY23. The sequential drop from Q3's 16.4% indicates specific cost pressures or pricing challenges hit hard in the final quarter, potentially related to raw material costs or competitive pricing in its key export markets.
Looking Ahead from a Position of Change
The company's near-term future is now tied to a corporate action. It was acquired by Innova Captab under insolvency proceedings, with the deal concluding on June 30, 2023. This brings both challenges and potential stability. The acquisition included an infusion of ₹195 crore, which should address the balance sheet stress evident in metrics like a negative ROCE and interest cover.
The broader API market outlook offers a mixed backdrop. Reports from Grand View Research and Ken Research highlight strong long-term growth drivers for India's API sector, including the global shift to generics and government initiatives. However, near-term challenges like dependence on imported raw materials and price competition persist.
Key Points
- Revenue for Q4 FY23 fell 23.4% sequentially and 11.1% year-on-year to ₹44.24 crore.
- Profit plummeted 81% quarter-on-quarter and 61.5% year-on-year to ₹1.8 crore, with the net margin collapsing to 4.1%.
- Full-year FY23 performance was stronger, with revenue up 21.8% and profit up 76.9%, aided by a one-time gain.
- The company was acquired by Innova Captab in June 2023, providing a capital infusion but also integrating it into a larger entity facing its own margin pressures.
Hexa Perspective
The quarter reveals a business hitting a rough patch at the exact moment of its corporate transition. The sharp margin contraction suggests operational headwinds—likely input costs and pricing—overwhelmed the model. The capital infusion from the acquisition removes an immediate solvency overhang, but the path to sustained profitability is unclear.
Investors are now weighing a weak standalone finish against the potential for stability and synergy under new ownership. The key will be whether the fresh capital and combined scale can help navigate the competitive API landscape better than Sharon could alone. The next few quarters will test that integration.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.